(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -17.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Macrogenics's revenue in 2026 is $167,673,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2026 to be $7,432,537,819, with the lowest MGNX revenue forecast at $3,683,144,812, and the highest MGNX revenue forecast at $11,087,017,547. On average, 8 Wall Street analysts forecast MGNX's revenue for 2027 to be $6,478,946,020, with the lowest MGNX revenue forecast at $3,745,570,996, and the highest MGNX revenue forecast at $10,393,959,513.
In 2028, MGNX is forecast to generate $6,059,289,188 in revenue, with the lowest revenue forecast at $4,557,111,378 and the highest revenue forecast at $8,475,946,882.